Phillip Samayoa
Founder of Generation Bio
Phillip Samayoa
Founder of Generation Bio
Cambridge, Massachusetts
Overview
Work Experience
Co-Founder and Chief Strategy Officer
2022 - Current
Senior Vice President, Head of Corporate Development
2021 - 2022
Vice President, Strategy and Portolio Development
2018 - 2021
Senior Director, Strategy and Portfolio Development
2017 - 2018
Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.
Raised $536,400,000.00 from Moderna.
Co-Founder
2017 - 2018
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Raised $940,100,000.00 from Logos Capital, Wellington Management, Vida Ventures, Franklin Templeton, Surveyor Capital, Forbion Capital Partners, Atlas Venture and MPM Capital.
Principal
2016 - 2018
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Board Observer
2015 - 2016
Principal, MRL Ventures
2016 - 2016
Associate, MRL Ventures
2015 - 2016
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.
Associate
2012 - 2015
VentureLabs Entrepreneurial Fellow
2012 - 2012
Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Co-Founder
2014 - 2015
Founding Team
2014 - 2014
Indigo is an agricultural technology company that focuses on improving sustainability and profitability in farming practices.
Raised $1,439,000,000.00 from State of Michigan Retirement System, Lingotto, Flagship Pioneering and Timon Capital.
Product Strategy and Intellectual Property
2012 - 2014
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Raised $185,500,000.00 from Fidelity, Nestlé Health Science and Flagship Pioneering.
Computational Systems Biology Intern
2009 - 2009